Senseonics Holdings Inc. has reached an agreement with Ascensia Diabetes Care Holdings AG to acquire certain assets related to the marketing, selling, and distribution of the Eversense® product in the United States. The transaction closed on January 1, 2026, with Senseonics also assuming certain related liabilities and obligations, including those connected to transferred employees. The agreement also outlines plans for Senseonics to acquire additional assets tied to Eversense CGM activities in Italy, Germany, Spain, and Sweden, subject to further negotiations and the execution of local agreements. The parties aim to finalize these European transactions by June 30, 2026, pending customary closing conditions and regulatory clearances.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Senseonics Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-000056), on January 02, 2026, and is solely responsible for the information contained therein.